Immune Design Corp. (IMDZ)

Oncology Corporate Profile

Stock Performance

6.9000
0.0000

HQ Location

1616 Eastlake Ave. E., Suite 310
Seattle, WA 98102

Company Description

Immune Design is a clinical-stage biotechnology company employing leading-edge technologies that target dendritic cells for a more precise immune response for the treatment of cancer and other chronic conditions. The company's clinical programs are the product of its two synergistic discovery platforms: DCVexTM, a novel lentiviral vector platform engineered to deliver antigen-encoding nucleic acids directly to dendritic cells in vivo, and GLAASTM, a TLR4-agonist platform that activates dendritic cells by up-regulating key molecules for efficient antigen presentation and produces Th1 cytokines to enhance the immune response.  

Website: http://www.immunedesign.com

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
LV 305 (+ atezolizumab)immunotherapySarcomaIIGenentech / Roche
LV 305 (+ pembrolizumab)immunotherapyMelanomaIMerck
ID-G100synthetic Toll-like receptor 4 agonistMerkel cell carcinomaI
LV305immunotherapyVarious cancer typesI
ID-G305immunotherapyVarious cancer typesI
LV 305 (+ pembrolizumab)immunotherapyNon-Hodgkin's Lymphoma (NHL)Merck
ID-G100 (+ pembrolizumab)immunotherapyMelanomaI Merck
ID-G100 (+ pembrolizumab)immunotherapyNon-Hodgkin's Lymphoma (NHL)I Merck

View additional information on product candidates here »

Source


http://www.immunedesign.com

Recent News Headlines

Immune Design Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update

3/7/2017 09:00 pm

[GlobeNewswire] - SEATTLE and SOUTH SAN FRANCISCO, Calif., March 07, 2017-- Immune Design, a clinical-stage immunotherapy company focused on oncology, today reported financial results and a corporate update for the fourth ...

Immune Design to Present New Tumor Eradication Data for Systemic Plus Intratumoral Immunization at the American Association for Cancer Research (AACR) Annual Meeting 2017

3/1/2017 10:02 pm

[GlobeNewswire] - –Preclinical Data Demonstrates Tumor Eradication with“ Prime-Pull” Immunotherapy Approach Combining a ZVex ® vector and G100–. –ZVex Causes Potent Activation of Dendritic Cells–. SEATTLE and SOUTH SAN ...

Immune Design to Report Fourth Quarter and Year End 2016 Financial Results and Provide Corporate Update

3/1/2017 09:00 pm

[GlobeNewswire] - SEATTLE and SOUTH SAN FRANCISCO, March 01, 2017-- Immune Design, a clinical-stage immunotherapy company focused on cancer, today announced that it will report fourth quarter and year end 2016 financial ...

Immune Design Receives Orphan Drug Designation for G100 Intratumoral Product Candidate

2/22/2017 01:00 pm

[GlobeNewswire] - SEATTLE and SOUTH SAN FRANCISCO, Calif., Feb. 22, 2017-- Immune Design, a clinical-stage immunotherapy company focused on oncology, today announced that the U.S. Food and Drug Administration has granted ...

Immune Design to Present at Upcoming Investor Conferences

2/10/2017 01:00 pm

[GlobeNewswire] - SEATTLE and SOUTH SAN FRANCISCO, Calif., Feb. 10, 2017-- Immune Design, a clinical-stage immunotherapy company focused on oncology, today announced that Carlos Paya, M.D., Ph.D., President and Chief Executive ...

Immune Design Provides Update from Two Discovery Platforms: DC-tropic ZVex Delivering Multiple Tumor Antigens (Conserved and Neo-Antigens) and G100 For Intratumoral Immunotherapy

12/5/2016 01:00 pm

[GlobeNewswire] - SEATTLE and SOUTH SAN FRANCISCO, Calif., Dec. 05, 2016-- Immune Design, a clinical-stage immunotherapy company focused on oncology, today announced new data that highlight the broad product reach potential ...

New Immune Design Data Highlights Expanded Product Potential of ZVex® Platform at the 2016 SITC Annual Meeting

11/11/2016 01:00 pm

[GlobeNewswire] - SEATTLE and SOUTH SAN FRANCISCO, Ca., Nov. 11, 2016-- Immune Design, a clinical-stage immunotherapy company focused on oncology, today announced new preclinical data demonstrating the ability of its ZVex ...